Diphtheria toxoid, Tetanus toxoid, and Pertussis antigens (DTaP/Tdap)

This target entry comprises a triad of bacterial components used primarily in vaccine formulations: the tetanus toxin from Clostridium tetani, the diphtheria toxin from Corynebacterium diphtheriae, and various antigens from Bordetella pertussis. Tetanus toxin is a zinc-dependent metalloprotease that cleaves synaptobrevin, preventing the release of inhibitory neurotransmitters and causing spastic paralysis (StatPearls, 2023). Diphtheria toxin acts as an ADP-ribosyltransferase that inactivates elongation factor 2 (EF-2), thereby halting host cell protein synthesis and leading to cell death (UniProt P00588). Pertussis antigens typically include pertussis toxin—another ADP-ribosyltransferase—alongside adhesins like filamentous hemagglutinin and pertactin, which facilitate bacterial colonization of the respiratory tract (CDC, 2022). In medical practice, these toxins are chemically inactivated into toxoids or processed into acellular subunits to serve as the basis for DTaP and Tdap vaccines. These vaccines stimulate the immune system to produce neutralizing antibodies, providing long-term protection against the life-threatening infections of tetanus, diphtheria, and whooping cough. The interaction between these antigens and the host immune system involves antigen presentation by dendritic cells and the subsequent activation of B and T lymphocytes. This multi-component target is unique in that it combines distinct molecular mechanisms of toxicity into a single therapeutic strategy for broad-spectrum prophylaxis.

Other names

DTPDTaPTdapTetanospasminDiphtheria toxinPertussis toxinFilamentous hemagglutininPertactinFimbriae types 2 and 3

Induction of active immunity through the production of neutralizing IgG antibodies against bacterial toxins and surface antigens.